Proneurogen

ProNeurogen is a clinical-stage biopharmaceutical company developing new treatments for vascular dementia by addressing its root cause at the level of the neurovascular unit. Vascular and mixed dementias contribute to approximately 75% of all cases of cognitive decline, yet the connection between the vascular system and brain has only recently been recognized as a major factor in disease progression. No therapies exist to modify or slow this process. ProNeurogen’s platform applies a validated Mas receptor mechanism to reduce neuroinflammation and improve brain-blood flow to protect cognition. By targeting the brain inflammation and decreased brain blood flow that drives cognitive decline, the company is defining the emerging field of Neuroprotective Therapeutics. Founded in 2013 as a University of Arizona spin-out by Dr Meredith Hay, ProNeurogen builds on decades of federally funded research and holds an exclusive global license for its patented intellectual property. Its platform integrates multiple analogs through a shared biomarker and manufacturing system developed through preclinical and early human research. Development has been supported through competitive NIH federal grants that uphold scientific rigor and accountability. The lead asset is progressing under FDA Fast Track review in vascular and mixed dementias, and the platform provides a path for expansion into additional neurovascular, neurodegenerative, and pain indications. ProNeurogen advances this work to redefine the future of neurovascular science to create enduring benefit for patients, families, and society.